Journal for ImmunoTherapy of Cancer

Title Publication Date Language Citations
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group2017/11/21English1,249
Cytokine release syndrome2018/06/15English936
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations2018/01/23English821
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy2017/07/18English608
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors2019/11/15English591
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors2019/10/26English536
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death2020/03/01English519
Clinical significance of tumor-infiltrating lymphocytes in breast cancer2016/10/18English462
Gene expression markers of Tumor Infiltrating Leukocytes2017/02/21English451
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)2019/07/15English379
TIGIT in cancer immunotherapy2020/09/01English355
Targeting adenosine for cancer immunotherapy2018/06/18English346
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy2016/08/16English345
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors2018/12/01English314
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project2020/03/01English288
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma2019/07/23English287
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events2021/06/01English283
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy2018/06/11English277
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)2018/05/16English273
Current clinical trials testing the combination of immunotherapy with radiotherapy2016/09/20English272
Mechanisms regulating PD-L1 expression on tumor and immune cells2019/11/15English271
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab2018/07/16English271
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment2017/12/01English270
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma2015/09/15English268
Combination immunotherapy: a road map2017/02/21English265
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)2018/06/22English263
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable2019/02/27English254
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma2019/06/06English249
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future2021/01/01English247
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy2016/09/20English243